NO20003721D0 - Farmasøytisk aktivt morfolinol - Google Patents

Farmasøytisk aktivt morfolinol

Info

Publication number: NO20003721D0
Authority: NO; Norway
Prior art keywords: pharmaceutically active; morpholinol; active morpholinol; pharmaceutically; active
Prior art date: 1998-01-21

Application number

NO20003721A

Other languages

English (en)

Other versions

NO20003721L (no

NO326878B1 (no

Inventor

Phillip Frederick Morgan

David Lee Musso

John Joseph Partidge

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

2000-07-20

Publication date

2000-07-20

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

2000-07-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-07-20 Publication of NO20003721D0 publication Critical patent/NO20003721D0/no

2000-09-19 Publication of NO20003721L publication Critical patent/NO20003721L/no

2009-03-09 Publication of NO326878B1 publication Critical patent/NO326878B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20003721A 1998-01-21 2000-07-20 Anvendelse av morfolinol NO326878B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (3)

Publication Number	Publication Date
NO20003721D0 true NO20003721D0 (no)	2000-07-20
NO20003721L NO20003721L (no)	2000-09-19
NO326878B1 NO326878B1 (no)	2009-03-09

Family

ID=26312986

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003721A NO326878B1 (no)	1998-01-21	2000-07-20	Anvendelse av morfolinol
NO20083529A NO20083529L (no)	1998-01-21	2008-08-14	Farmasoytisk aktivt morfolinol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20083529A NO20083529L (no)	1998-01-21	2008-08-14	Farmasoytisk aktivt morfolinol

Country Status (30)

Country	Link
US (2)	US6274579B1 (no)
EP (2)	EP1047428B1 (no)
JP (1)	JP2002501025A (no)
KR (1)	KR100568063B1 (no)
CN (2)	CN1203858C (no)
AP (1)	AP1229A (no)
AT (1)	ATE365042T1 (no)
AU (1)	AU755536B2 (no)
BR (1)	BR9907203A (no)
CA (1)	CA2318268A1 (no)
CY (1)	CY1106828T1 (no)
DE (1)	DE69936335T2 (no)
DK (1)	DK1047428T3 (no)
EA (1)	EA002410B1 (no)
EE (1)	EE04452B1 (no)
ES (1)	ES2288012T3 (no)
HR (2)	HRP20000494B1 (no)
HU (1)	HUP0100900A3 (no)
ID (1)	ID26334A (no)
IL (2)	IL137346A0 (no)
IS (1)	IS2494B (no)
NO (2)	NO326878B1 (no)
NZ (3)	NZ505809A (no)
PL (1)	PL193622B1 (no)
PT (1)	PT1047428E (no)
SG (1)	SG115489A1 (no)
SK (1)	SK10912000A3 (no)
TR (1)	TR200002126T2 (no)
WO (1)	WO1999037305A1 (no)
YU (1)	YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en)	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6458374B1 (en)	1998-01-29	2002-10-01	Sepracor, Inc.	Methods and compositions for treating chronic disorders using optically pure (+)-bupropion
EP1051167A1 (en)	1998-01-29	2000-11-15	Sepracor, Inc.	Pharmaceutical uses of optically pure (-) -bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
WO2001026641A2 (en) *	1999-10-13	2001-04-19	Glaxo Group Limited	Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
US7109198B2 (en) *	2002-05-17	2006-09-19	Duke University	Method for treating obesity
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
DE60324685D1 (de) *	2002-08-23	2008-12-24	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
ES2760464T3 (es)	2003-04-29	2020-05-14	Nalpropion Pharmaceuticals Inc	Composiciones para afectar a la pérdida de peso
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
JP2007509856A (ja) *	2003-10-27	2007-04-19	スミスクラインビーチャムコーポレーション	（＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
KR20060128995A (ko) *	2004-01-13	2006-12-14	듀크 유니버시티	체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
WO2005110405A1 (en) *	2004-05-03	2005-11-24	Duke University	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
CN101370488B (zh)	2005-11-22	2012-07-18	奥雷西根治疗公司	增加胰岛素敏感性的组合物
MX2008008694A (es) *	2006-01-03	2009-01-07	Algebra Inc	Compuestos conjugados de amina terapeutica-arilsulfonamida.
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
JP2010509367A (ja)	2006-11-09	2010-03-25	オレキシジェン・セラピューティクス・インコーポレーテッド	積層製剤
KR20180066272A (ko)	2006-11-09	2018-06-18	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
AU2010236404B2 (en)	2009-04-15	2016-11-03	Research Triangle Institute	Monoamine reuptake inhibitors
MX344303B (es)	2010-01-11	2016-12-13	Orexigen Therapeutics Inc	Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
JP5952267B2 (ja)	2010-05-21	2016-07-13	リサーチ・トライアングル・インスティチュート	薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
WO2011146850A1 (en)	2010-05-21	2011-11-24	Research Triangle Institute	Phenylmorpholines and analogues thereof
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
CA2875056C (en)	2012-06-06	2024-03-26	Orexigen Therapeutics, Inc.	Methods of treating overweight and obesity
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en)	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active IP Right Cessation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en active IP Right Grant
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-21 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2005
- 2005-12-29 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE69936335D1 (de)	2007-08-02
CN1528753A (zh)	2004-09-15
IS2494B (is)	2009-02-15
NO20083529L (no)	2000-09-19
BR9907203A (pt)	2000-10-17
TR200002126T2 (tr)	2000-12-21
CN1255389C (zh)	2006-05-10
NZ520349A (en)	2004-02-27
AP2000001869A0 (en)	2000-09-30
NZ505809A (en)	2002-09-27
IL161942A0 (en)	2005-11-20
AU755536B2 (en)	2002-12-12
CY1106828T1 (el)	2012-05-23
DE69936335T2 (de)	2008-02-28
NO20003721L (no)	2000-09-19
KR100568063B1 (ko)	2006-04-07
PL193622B1 (pl)	2007-02-28
ATE365042T1 (de)	2007-07-15
HRP20051024A2 (hr)	2006-04-30
YU67102A (sh)	2004-12-31
EP1047428A4 (en)	2001-12-19
DK1047428T3 (da)	2007-10-08
US20020019396A1 (en)	2002-02-14
EA002410B1 (ru)	2002-04-25
US6274579B1 (en)	2001-08-14
WO1999037305A1 (en)	1999-07-29
IL137346A0 (en)	2001-07-24
HRP20000494B1 (en)	2009-02-28
CN1294513A (zh)	2001-05-09
HUP0100900A3 (en)	2002-08-28
CA2318268A1 (en)	1999-07-29
AP1229A (en)	2003-12-04
US6391875B2 (en)	2002-05-21
IS5568A (is)	2000-07-20
HUP0100900A2 (hu)	2002-05-29
SG115489A1 (en)	2005-10-28
HRP20000494A2 (en)	2000-12-31
EE04452B1 (et)	2005-04-15
EE200000438A (et)	2001-12-17
AU2328099A (en)	1999-08-09
PL342012A1 (en)	2001-05-07
CN1203858C (zh)	2005-06-01
NO326878B1 (no)	2009-03-09
ID26334A (id)	2000-12-14
EP1047428A1 (en)	2000-11-02
EP1829544A1 (en)	2007-09-05
EP1047428B1 (en)	2007-06-20
KR20010034285A (ko)	2001-04-25
SK10912000A3 (sk)	2001-04-09
JP2002501025A (ja)	2002-01-15
NZ529316A (en)	2004-05-28
PT1047428E (pt)	2007-09-07
ES2288012T3 (es)	2007-12-16
EA200000691A1 (ru)	2001-04-23

Publication	Publication Date	Title
NO20003721D0 (no)	2000-07-20	Farmasøytisk aktivt morfolinol
PT1220856E (pt)	2005-02-28	Compostos farmaceuticamente activos
NL350038I2 (nl)	2009-01-05	Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DE69926752D1 (de)	2005-09-22	Therapeutisch wirksame biaryl-derivate
GB9823101D0 (en)	1998-12-16	Pharmaceutically active compounds
DE50007846D1 (de)	2004-10-28	Dreschkorb
DE60009395D1 (de)	2004-05-06	Bildanzeige
MA26473A1 (fr)	2004-12-20	Composes pharmacologiquement actifs.
DK1218374T3 (da)	2005-12-27	Farmaceutisk aktive sulfonamidderivater
NO992692D0 (no)	1999-06-03	Nefadozon doseringsform
GB9823102D0 (en)	1998-12-16	Pharmaceutically active compounds
NO993443L (no)	2000-01-14	Kabinstruktur
DE50015795D1 (de)	2009-12-24	Sektionaltor
NO20012965D0 (no)	2001-06-15	Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DE59902159D1 (de)	2002-08-29	Aktiver mikromischer
NO20005769L (no)	2000-11-14	Cyklosporinderivater
DE59903807D1 (de)	2003-01-30	Wirkstoffkonzentrat
SE9802539D0 (sv)	1998-07-13	New pharmaceutically active compounds
IS8740A (is)	2008-06-27	Lyfjafræðilega virkt morfólínól
SE9700660D0 (sv)	1997-02-25	Pharmaceutically active compounds
ATA203199A (de)	2001-03-15	Ablauf
SE9704874D0 (sv)	1997-12-23	New pharmaceutically active compounds
DE60004561D1 (de)	2003-09-18	Aktive baugruppe
SE9901854D0 (sv)	1999-05-21	New pharmaceutically active compounds
IL158978A0 (en)	2004-05-12	Pharmaceutically active morpholinol

Legal Events

Date	Code	Title	Description
2013-08-26	MM1K	Lapsed by not paying the annual fees